nodes	percent_of_prediction	percent_of_DWPC	metapath
Pranlukast—ABCC2—Carboplatin—uterine cancer	0.112	0.193	CbGbCtD
Pranlukast—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.107	0.183	CbGbCtD
Pranlukast—ABCC2—Etoposide—uterine cancer	0.0941	0.162	CbGbCtD
Pranlukast—CYP2C9—Progesterone—uterine cancer	0.0706	0.121	CbGbCtD
Pranlukast—ABCC2—Doxorubicin—uterine cancer	0.0642	0.11	CbGbCtD
Pranlukast—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.062	0.107	CbGbCtD
Pranlukast—CYP3A4—Progesterone—uterine cancer	0.0411	0.0706	CbGbCtD
Pranlukast—IL5—exocrine gland—uterine cancer	0.025	0.148	CbGeAlD
Pranlukast—MUC2—exocrine gland—uterine cancer	0.0192	0.114	CbGeAlD
Pranlukast—CYP3A4—Etoposide—uterine cancer	0.0184	0.0316	CbGbCtD
Pranlukast—CYP3A4—Doxorubicin—uterine cancer	0.0125	0.0216	CbGbCtD
Pranlukast—IL5—epithelium—uterine cancer	0.0109	0.0644	CbGeAlD
Pranlukast—MUC2—epithelium—uterine cancer	0.00837	0.0496	CbGeAlD
Pranlukast—MUC2—renal system—uterine cancer	0.00777	0.046	CbGeAlD
Pranlukast—MUC2—female reproductive system—uterine cancer	0.00622	0.0368	CbGeAlD
Pranlukast—NFKB1—myometrium—uterine cancer	0.00608	0.036	CbGeAlD
Pranlukast—MUC2—female gonad—uterine cancer	0.00566	0.0335	CbGeAlD
Pranlukast—TNF—vagina—uterine cancer	0.00563	0.0333	CbGeAlD
Pranlukast—NFKB1—uterine cervix—uterine cancer	0.00473	0.028	CbGeAlD
Pranlukast—IL5—lymph node—uterine cancer	0.00473	0.028	CbGeAlD
Pranlukast—CYSLTR1—smooth muscle tissue—uterine cancer	0.00452	0.0267	CbGeAlD
Pranlukast—NFKB1—decidua—uterine cancer	0.00451	0.0267	CbGeAlD
Pranlukast—NFKB1—renal system—uterine cancer	0.00443	0.0262	CbGeAlD
Pranlukast—NFKB1—endometrium—uterine cancer	0.00428	0.0253	CbGeAlD
Pranlukast—NFKB1—mammalian vulva—uterine cancer	0.00414	0.0245	CbGeAlD
Pranlukast—CYSLTR1—mammalian vulva—uterine cancer	0.00407	0.0241	CbGeAlD
Pranlukast—NFKB1—uterus—uterine cancer	0.00395	0.0233	CbGeAlD
Pranlukast—CYSLTR1—uterus—uterine cancer	0.00388	0.0229	CbGeAlD
Pranlukast—TNF—lymph node—uterine cancer	0.00364	0.0215	CbGeAlD
Pranlukast—Ospemifene—ESR1—uterine cancer	0.00364	1	CrCbGaD
Pranlukast—NFKB1—female reproductive system—uterine cancer	0.00355	0.021	CbGeAlD
Pranlukast—CYSLTR1—female reproductive system—uterine cancer	0.00348	0.0206	CbGeAlD
Pranlukast—NFKB1—female gonad—uterine cancer	0.00323	0.0191	CbGeAlD
Pranlukast—NFKB1—vagina—uterine cancer	0.00321	0.019	CbGeAlD
Pranlukast—CYSLTR1—vagina—uterine cancer	0.00315	0.0186	CbGeAlD
Pranlukast—NFKB1—lymph node—uterine cancer	0.00207	0.0123	CbGeAlD
Pranlukast—CYSLTR1—lymph node—uterine cancer	0.00204	0.0121	CbGeAlD
Pranlukast—ABCC2—renal system—uterine cancer	0.00174	0.0103	CbGeAlD
Pranlukast—ABCC2—female reproductive system—uterine cancer	0.00139	0.00824	CbGeAlD
Pranlukast—CYP2C9—female reproductive system—uterine cancer	0.000928	0.00549	CbGeAlD
Pranlukast—CYP3A4—renal system—uterine cancer	0.000883	0.00523	CbGeAlD
Pranlukast—ABCC2—lymph node—uterine cancer	0.000815	0.00482	CbGeAlD
Pranlukast—CYP3A4—female reproductive system—uterine cancer	0.000707	0.00419	CbGeAlD
Pranlukast—NFKB1—Innate Immune System—FGFR2—uterine cancer	9.86e-05	0.000401	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—TP53—uterine cancer	9.85e-05	0.0004	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	9.82e-05	0.000399	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—TP53—uterine cancer	9.77e-05	0.000397	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	9.74e-05	0.000396	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—TP53—uterine cancer	9.67e-05	0.000393	CbGpPWpGaD
Pranlukast—NFKB1—B Cell Activation—KRAS—uterine cancer	9.66e-05	0.000392	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—NRAS—uterine cancer	9.63e-05	0.000391	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—RNF43—uterine cancer	9.63e-05	0.000391	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—FBXW7—uterine cancer	9.61e-05	0.000391	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—MET—uterine cancer	9.59e-05	0.00039	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—PIK3CA—uterine cancer	9.59e-05	0.00039	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—SMAD3—uterine cancer	9.58e-05	0.000389	CbGpPWpGaD
Pranlukast—NFKB1—Regulation of toll-like receptor signaling pathway—AKT1—uterine cancer	9.5e-05	0.000386	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—FGFR2—uterine cancer	9.47e-05	0.000385	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—HRAS—uterine cancer	9.42e-05	0.000383	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—EP300—uterine cancer	9.41e-05	0.000383	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IRF1—uterine cancer	9.39e-05	0.000382	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	9.3e-05	0.000378	CbGpPWpGaD
Pranlukast—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—uterine cancer	9.29e-05	0.000378	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.29e-05	0.000378	CbGpPWpGaD
Pranlukast—TNF—Toll-like Receptor Signaling Pathway—AKT1—uterine cancer	9.27e-05	0.000377	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—PTEN—uterine cancer	9.26e-05	0.000376	CbGpPWpGaD
Pranlukast—NFKB1—BDNF signaling pathway—AKT1—uterine cancer	9.24e-05	0.000375	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—CXCL8—uterine cancer	9.21e-05	0.000374	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	9.17e-05	0.000373	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—FGFR2—uterine cancer	9.14e-05	0.000371	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	9.05e-05	0.000368	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	9.05e-05	0.000368	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	9.02e-05	0.000367	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—SMAD3—uterine cancer	8.92e-05	0.000362	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—VEGFA—uterine cancer	8.91e-05	0.000362	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—TP53—uterine cancer	8.91e-05	0.000362	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	8.89e-05	0.000361	CbGpPWpGaD
Pranlukast—IL5—Immune System—ERBB2—uterine cancer	8.87e-05	0.000361	CbGpPWpGaD
Pranlukast—NFKB1—B Cell Activation—PIK3CA—uterine cancer	8.87e-05	0.000361	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—uterine cancer	8.87e-05	0.00036	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—PIK3CA—uterine cancer	8.86e-05	0.00036	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—INHBA—uterine cancer	8.81e-05	0.000358	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	8.8e-05	0.000358	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	8.72e-05	0.000355	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	8.66e-05	0.000352	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—FBXW7—uterine cancer	8.41e-05	0.000342	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—NRAS—uterine cancer	8.4e-05	0.000341	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—STK11—uterine cancer	8.4e-05	0.000341	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—CCL2—uterine cancer	8.36e-05	0.00034	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—AKT1—uterine cancer	8.32e-05	0.000338	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—KRAS—uterine cancer	8.29e-05	0.000337	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—NRAS—uterine cancer	8.26e-05	0.000336	CbGpPWpGaD
Pranlukast—IL5—Immune System—CDKN1B—uterine cancer	8.22e-05	0.000334	CbGpPWpGaD
Pranlukast—NFKB1—B Cell Activation—HRAS—uterine cancer	8.21e-05	0.000334	CbGpPWpGaD
Pranlukast—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—AKT1—uterine cancer	8.2e-05	0.000333	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—AKT1—uterine cancer	8.16e-05	0.000332	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—AKR1C1—uterine cancer	7.93e-05	0.000322	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—SOCS3—uterine cancer	7.86e-05	0.00032	CbGpPWpGaD
Pranlukast—TNF—Apoptosis—TP53—uterine cancer	7.86e-05	0.000319	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	7.83e-05	0.000318	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ESR1—uterine cancer	7.82e-05	0.000318	CbGpPWpGaD
Pranlukast—IL5—Immune System—CTNNB1—uterine cancer	7.76e-05	0.000316	CbGpPWpGaD
Pranlukast—IL5—Immune System—PTEN—uterine cancer	7.57e-05	0.000308	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CDKN2B—uterine cancer	7.53e-05	0.000306	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	7.48e-05	0.000304	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—NRAS—uterine cancer	7.39e-05	0.0003	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	7.37e-05	0.000299	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—TP53—uterine cancer	7.37e-05	0.000299	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IGF1R—uterine cancer	7.31e-05	0.000297	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—MET—uterine cancer	7.31e-05	0.000297	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—CXCL8—uterine cancer	7.28e-05	0.000296	CbGpPWpGaD
Pranlukast—NFKB1—B Cell Activation—AKT1—uterine cancer	7.25e-05	0.000295	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—AKT1—uterine cancer	7.24e-05	0.000294	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—KRAS—uterine cancer	7.23e-05	0.000294	CbGpPWpGaD
Pranlukast—IL5—Immune System—EP300—uterine cancer	7.22e-05	0.000293	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—KRAS—uterine cancer	7.11e-05	0.000289	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—CDH1—uterine cancer	7.05e-05	0.000286	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—ERBB2—uterine cancer	7.01e-05	0.000285	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—SOCS3—uterine cancer	6.89e-05	0.00028	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CCL2—uterine cancer	6.88e-05	0.00028	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—SMAD3—uterine cancer	6.87e-05	0.000279	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	6.87e-05	0.000279	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	6.84e-05	0.000278	CbGpPWpGaD
Pranlukast—IL5—Immune System—NRAS—uterine cancer	6.75e-05	0.000274	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	6.75e-05	0.000274	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—TP53—uterine cancer	6.73e-05	0.000274	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	6.65e-05	0.00027	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.64e-05	0.00027	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	6.64e-05	0.00027	CbGpPWpGaD
Pranlukast—TNF—Apoptosis—AKT1—uterine cancer	6.63e-05	0.00027	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—CXCL8—uterine cancer	6.61e-05	0.000269	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—FGFR2—uterine cancer	6.56e-05	0.000267	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—PIK3CA—uterine cancer	6.53e-05	0.000265	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—PIK3CA—uterine cancer	6.43e-05	0.000262	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—KRAS—uterine cancer	6.36e-05	0.000258	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—AKT1—uterine cancer	6.22e-05	0.000253	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—ERBB2—uterine cancer	6.19e-05	0.000252	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—HRAS—uterine cancer	6.14e-05	0.00025	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—CTNNB1—uterine cancer	6.13e-05	0.000249	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—AKR1C3—uterine cancer	6.1e-05	0.000248	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—HRAS—uterine cancer	6.04e-05	0.000246	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PGR—uterine cancer	5.95e-05	0.000242	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—ERBB2—uterine cancer	5.94e-05	0.000242	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—PIK3CA—uterine cancer	5.84e-05	0.000237	CbGpPWpGaD
Pranlukast—IL5—Immune System—KRAS—uterine cancer	5.81e-05	0.000236	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—FGFR2—uterine cancer	5.74e-05	0.000233	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ERBB2—uterine cancer	5.74e-05	0.000233	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—CDKN1B—uterine cancer	5.73e-05	0.000233	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—EP300—uterine cancer	5.7e-05	0.000232	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—YWHAE—uterine cancer	5.67e-05	0.000231	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.61e-05	0.000228	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ESR1—uterine cancer	5.61e-05	0.000228	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—SRD5A2—uterine cancer	5.58e-05	0.000227	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NDUFB11—uterine cancer	5.58e-05	0.000227	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—CDKN1B—uterine cancer	5.51e-05	0.000224	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FBXW7—uterine cancer	5.44e-05	0.000221	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CXCL8—uterine cancer	5.44e-05	0.000221	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—CTNNB1—uterine cancer	5.42e-05	0.00022	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	5.42e-05	0.00022	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—HRAS—uterine cancer	5.41e-05	0.00022	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—VEGFA—uterine cancer	5.4e-05	0.000219	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—ERBB2—uterine cancer	5.34e-05	0.000217	CbGpPWpGaD
Pranlukast—IL5—Immune System—PIK3CA—uterine cancer	5.34e-05	0.000217	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—AKT1—uterine cancer	5.33e-05	0.000217	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—NRAS—uterine cancer	5.33e-05	0.000217	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CDKN1B—uterine cancer	5.31e-05	0.000216	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—NRAS—uterine cancer	5.3e-05	0.000216	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—PTEN—uterine cancer	5.28e-05	0.000215	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—AKT1—uterine cancer	5.26e-05	0.000214	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	5.11e-05	0.000208	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—PTEN—uterine cancer	5.07e-05	0.000206	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—EP300—uterine cancer	5.03e-05	0.000205	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CTNNB1—uterine cancer	5.02e-05	0.000204	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CCL2—uterine cancer	4.94e-05	0.000201	CbGpPWpGaD
Pranlukast—IL5—Immune System—HRAS—uterine cancer	4.94e-05	0.000201	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—PTEN—uterine cancer	4.89e-05	0.000199	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—AKT1—uterine cancer	4.77e-05	0.000194	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—STK11—uterine cancer	4.76e-05	0.000193	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—NRAS—uterine cancer	4.71e-05	0.000191	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—CTNNB1—uterine cancer	4.67e-05	0.00019	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—EP300—uterine cancer	4.67e-05	0.00019	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—PIK3CA—uterine cancer	4.62e-05	0.000188	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—KRAS—uterine cancer	4.59e-05	0.000187	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—KRAS—uterine cancer	4.56e-05	0.000186	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—NRAS—uterine cancer	4.52e-05	0.000184	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—SOCS3—uterine cancer	4.45e-05	0.000181	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—VEGFA—uterine cancer	4.42e-05	0.00018	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—NRAS—uterine cancer	4.36e-05	0.000177	CbGpPWpGaD
Pranlukast—IL5—Immune System—AKT1—uterine cancer	4.36e-05	0.000177	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—EP300—uterine cancer	4.34e-05	0.000177	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CDH1—uterine cancer	4.27e-05	0.000174	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CDKN2B—uterine cancer	4.26e-05	0.000173	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—PIK3CA—uterine cancer	4.19e-05	0.00017	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IGF1R—uterine cancer	4.14e-05	0.000168	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ERBB2—uterine cancer	4.12e-05	0.000167	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—VEGFA—uterine cancer	4.11e-05	0.000167	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—NRAS—uterine cancer	4.06e-05	0.000165	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—KRAS—uterine cancer	4.05e-05	0.000165	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—AKR1B1—uterine cancer	4.03e-05	0.000164	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—STAR—uterine cancer	4.03e-05	0.000164	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.98e-05	0.000162	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CXCL8—uterine cancer	3.9e-05	0.000159	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—HRAS—uterine cancer	3.9e-05	0.000159	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—KRAS—uterine cancer	3.89e-05	0.000158	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—SMAD3—uterine cancer	3.89e-05	0.000158	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—HRAS—uterine cancer	3.88e-05	0.000158	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CDKN1B—uterine cancer	3.81e-05	0.000155	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—AKT1—uterine cancer	3.77e-05	0.000153	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—KRAS—uterine cancer	3.76e-05	0.000153	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—PIK3CA—uterine cancer	3.72e-05	0.000151	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGFR2—uterine cancer	3.71e-05	0.000151	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.68e-05	0.000149	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.68e-05	0.000149	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—ERBB2—uterine cancer	3.61e-05	0.000147	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CTNNB1—uterine cancer	3.6e-05	0.000146	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—PIK3CA—uterine cancer	3.58e-05	0.000145	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PTEN—uterine cancer	3.51e-05	0.000143	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—KRAS—uterine cancer	3.5e-05	0.000142	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—PIK3CA—uterine cancer	3.45e-05	0.00014	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—HRAS—uterine cancer	3.45e-05	0.00014	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—AKT1—uterine cancer	3.44e-05	0.00014	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—AKT1—uterine cancer	3.43e-05	0.000139	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—EP300—uterine cancer	3.35e-05	0.000136	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CDKN1B—uterine cancer	3.34e-05	0.000136	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TP53—uterine cancer	3.34e-05	0.000136	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HRAS—uterine cancer	3.31e-05	0.000134	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—HRAS—uterine cancer	3.19e-05	0.00013	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ESR1—uterine cancer	3.18e-05	0.000129	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—VEGFA—uterine cancer	3.17e-05	0.000129	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—POLD1—uterine cancer	3.16e-05	0.000129	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CTNNB1—uterine cancer	3.15e-05	0.000128	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—NRAS—uterine cancer	3.13e-05	0.000127	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PTEN—uterine cancer	3.07e-05	0.000125	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—AKT1—uterine cancer	3.04e-05	0.000124	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—HRAS—uterine cancer	2.97e-05	0.000121	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—AKR1C1—uterine cancer	2.96e-05	0.00012	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—EP300—uterine cancer	2.93e-05	0.000119	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—AKT1—uterine cancer	2.92e-05	0.000119	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—AKT1—uterine cancer	2.82e-05	0.000115	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CCL2—uterine cancer	2.8e-05	0.000114	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—NRAS—uterine cancer	2.74e-05	0.000112	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—KRAS—uterine cancer	2.7e-05	0.00011	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.66e-05	0.000108	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—STAR—uterine cancer	2.66e-05	0.000108	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—RRM2—uterine cancer	2.64e-05	0.000107	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—AKT1—uterine cancer	2.62e-05	0.000107	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—DCN—uterine cancer	2.56e-05	0.000104	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PIK3CA—uterine cancer	2.48e-05	0.000101	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYP11A1—uterine cancer	2.41e-05	9.8e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TP53—uterine cancer	2.4e-05	9.74e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—KRAS—uterine cancer	2.36e-05	9.6e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ERBB2—uterine cancer	2.33e-05	9.48e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—HRAS—uterine cancer	2.29e-05	9.32e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—AKR1C3—uterine cancer	2.28e-05	9.26e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CXCL8—uterine cancer	2.21e-05	8.99e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PIK3CA—uterine cancer	2.17e-05	8.82e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CDKN1B—uterine cancer	2.16e-05	8.78e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—POLD1—uterine cancer	2.09e-05	8.48e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CTNNB1—uterine cancer	2.04e-05	8.29e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—AKT1—uterine cancer	2.02e-05	8.22e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HRAS—uterine cancer	2.01e-05	8.16e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTEN—uterine cancer	1.99e-05	8.08e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.95e-05	7.93e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—EP300—uterine cancer	1.9e-05	7.71e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—VEGFA—uterine cancer	1.8e-05	7.3e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—STK11—uterine cancer	1.77e-05	7.21e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.77e-05	7.21e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NRAS—uterine cancer	1.77e-05	7.21e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—AKT1—uterine cancer	1.77e-05	7.2e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—RRM2—uterine cancer	1.74e-05	7.07e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—DCN—uterine cancer	1.69e-05	6.86e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.67e-05	6.77e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.59e-05	6.47e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.59e-05	6.46e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—KRAS—uterine cancer	1.53e-05	6.2e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.5e-05	6.11e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PIK3CA—uterine cancer	1.4e-05	5.7e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TP53—uterine cancer	1.36e-05	5.51e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MTHFR—uterine cancer	1.33e-05	5.42e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HRAS—uterine cancer	1.3e-05	5.27e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.18e-05	4.78e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—STK11—uterine cancer	1.17e-05	4.76e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.17e-05	4.76e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—AKT1—uterine cancer	1.15e-05	4.66e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MTHFR—uterine cancer	8.79e-06	3.57e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PTEN—uterine cancer	7.42e-06	3.02e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—EP300—uterine cancer	7.07e-06	2.88e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PIK3CA—uterine cancer	5.23e-06	2.13e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PTEN—uterine cancer	4.89e-06	1.99e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—EP300—uterine cancer	4.67e-06	1.9e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—AKT1—uterine cancer	4.28e-06	1.74e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PIK3CA—uterine cancer	3.45e-06	1.4e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—AKT1—uterine cancer	2.82e-06	1.15e-05	CbGpPWpGaD
